Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US firm PediatRx has signed a co-promotion agreement with Bi-Coastal Pharmaceutical for Aquoral.
Subscribe to our email newsletter
The US Food and Drug Administration (FDA) approved Aquoral is indicated for the treatment of xerostomia.
PediatRx founder Cameron Durrant said they expect that Aquoral will help further establish the company in the oncology supportive care arena.
"With both Aquoral and Granisol focused on a similar target audience, this allows us to leverage our existing infrastructure, which was previously solely supporting Granisol, and is congruent with our strategy of adding complementary products," Durrant said.